Q-omics provides the consensus-scored KIF19 profile across patient tissues and cancer cell-line models. KIF19 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KIF19 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, KIF19 RNA expression shows 13,864 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, THCA, and GBM as cancer lineages where KIF19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF19 survival associations across molecular data types. KIF19 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF19 RNA expression–survival associations across cancer types. High KIF19 expression shows unfavorable associations in KIRP, KIRC and OV, but favorable associations in SKCM, PAAD and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KIF19 RNA expression.
This table summarizes KIF19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KIF19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF19 shows lower tumor expression in THCA, LUSC, LUAD, LIHC and COAD and higher tumor expression in KIRC. The THCA box plot shows higher KIF19 RNA expression in normal versus tumor tissue (log2 FC = −1.968, t-test p < 0.001).
This table shows molecular features associated with KIF19 in patient tissues and cancer cell lines. In patient samples, KIF19 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
